Acute Coronary Syndrome Clinical Trials

Find Acute Coronary Syndrome Clinical Trials Near You

Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation on Alleviating Major Depressive Disorder in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention:A Prospective, Double-Blind,Randomized Controlled Study

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a randomized, controlled study. ACS follow- up patients aged 18 to 80 years old with hemodynamic stability, who are 14 days to 1 year after PCI, are screened through the HAMD score and the HAMA score. Patients with a HAMD score greater than 7 points and a HAMD score higher than that of the HAMA, are included in this study. Patients were allocated to the active taVNS group or sham taVNS group with a 1:1 ratio. Both groups received the stimulation for 20 minutes each time, twice a day with an 8-week treatment and a 8-week follow-up. All treatments were self-administered by the patients at home after they received training from the hospitals. The primary observation endpoints include the depression scores of the HAMD. The secondary observation endpoints include the HAMA 、GAD、 response and remission rates of HAMD ,as well as the PCL-C for post-traumatic stress disorder. We also observed the cardiac function indexes measured by echocardiography and the B-type natriuretic peptide .

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years

• Meeting the diagnostic criteria for ACS

• 14 days to 12 months after successful PCI, with stable vital signs

• Meeting the diagnostic criteria for depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)

• HAMD-17 score ≥7 and \<24 (mild-to-moderate depression), with HAMA score \<HAMD score;

• Refusal of psychiatric consultation, antidepressant medication, or psychological therapy by the patient or their legal representative after full informed consent

• Voluntary participation in the study and signing of the informed consent form

Locations
Other Locations
China
Tang-Du Hospital,Department of Cardiology
RECRUITING
Xi'an
Contact Information
Primary
jing Han, Pursuing Master's Degree
710694996@qq.com
8618506576253
Backup
wangang Guo, Doctor of Philosophy
Guowagon@qq.com
8618629581753
Time Frame
Start Date: 2026-01-06
Estimated Completion Date: 2026-08-10
Participants
Target number of participants: 120
Treatments
Experimental: Transcutaneous Auricular Vagus Nerve Stimulation Intervention (taVNS)
Participants in this arm receive the active transcutaneous auricular vagus nerve stimulation (taVNS) intervention as defined in the corresponding Intervention section. The intervention is administered twice daily for 20 minutes per session, continuously for 8 weeks, with weekly follow-up visits to assess depressive symptoms and stimulation safety.
Sham_comparator: Sham Transcutaneous Auricular Vagus Nerve Stimulation Control(sham taVNS)
Participants in this arm receive the sham transcutaneous auricular vagus nerve stimulation (sham taVNS) intervention as defined in the corresponding Intervention section. The sham intervention is delivered twice daily for 20 minutes per session over 8 weeks, matching the active group in procedure duration and frequency to maintain participant blinding, with weekly follow-up assessments identical to the active arm.
Sponsors
Leads: Jing Han

This content was sourced from clinicaltrials.gov